50 results on '"Dammann, Elke"'
Search Results
2. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation
3. Adaptive NK cells undergo a dynamic modulation in response to human cytomegalovirus and recruit T cells in in vitro migration assays
4. Deep Analysis of AKI and CKD in Allogeneic Stem Cell Transplantation: A Big Data Approach: PUB245
5. Increased Late Noncardiac Nonrelapse Mortality in Patients with Atrial Fibrillation Diagnosed During Their Hospital Stay for Allogeneic Stem Cell Transplantation
6. Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients
7. Possible Impact of Cytomegalovirus-Specific CD8+ T Cells on Immune Reconstitution and Conversion to Complete Donor Chimerism after Allogeneic Stem Cell Transplantation
8. Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry
9. Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse
10. Navigating preemptive and therapeutic donor lymphocyte infusions in advanced myeloid malignancies by high-sensitivity chimerism analysis
11. MO343: Deep Analysis of The AKI—CKD in Allogeneic Stem Cell Transplantation—A Big Data Approach
12. Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML
13. Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia
14. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome
15. FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia
16. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk
17. Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation
18. T Regulatory Cell Receptor Repertoire Focusing and Clonal Expansion Indicates Control of Acute GvHD after Donor Lymphocyte Infusion
19. Cumulative dosages of chemotherapy and radiotherapy exposure, and risk of secondary malignancies after allogeneic hematopoietic stem cell transplantation
20. FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
21. Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation
22. Characterization of High-Avidity Cytomegalovirus-Specific T Cells with Differential Tetramer Binding Coappearing after Allogeneic Stem Cell Transplantation
23. TCR Diversity Is a Predictive Marker for Donor Lymphocyte Infusion Response
24. Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation
25. Cumulative dosages of chemotherapy and radiotherapy exposure, and risk of secondary malignancies after allogeneic hematopoietic stem cell transplantation
26. Prognostic Impact Of a Newly Defined Structurally Complex Karyotype In Patients With AML and MDS After Allogeneic Stem Cell Transplantation
27. Graft Versus Leukemia With Little Graft Versus Host Disease? Long Term Follow-Up Of a Study Using Transduced Donor T-Cells For Donor Leukocyte Transfusion
28. Correction: Sequential Anti-Cytomegalovirus Response Monitoring May Allow Prediction of Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation
29. Sequential Anti-Cytomegalovirus Response Monitoring May Allow Prediction of Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation
30. Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
31. Prognostic Effect of Mutations in the Splicing Gene Machinery in 339 Patients with MDS or Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation
32. Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation
33. Persistence of Recipient-Derived Antiviral T cells Severely Influence Donor Chimerism Post Allogeneic HSCT,
34. Prospective Validation of a Chronic GvHD-Specific Proteome Pattern (cGvHD-MS14) Post Allogeneic Hematopoietic Stem Cell Transplantation
35. Proteomic Pattern-Based Risk Stratification of Outcome Shows Significant Higher Accuracy Compared to HCT-CI in Patients with AML and MDS,
36. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome
37. High lethality of human adenovirus disease in adult allogeneic stem cell transplant recipients with high adenoviral blood load
38. Genetically Modified Donor Leukocyte Transfusion and Graft-Versus-Leukemia Effect After Allogeneic Stem Cell Transplantation
39. Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with Normal Karyotype: A Risk Factor Analysis in 247 Patients, Based On Molecular Markers and Stage at Transplantation.
40. Long Term Results of Allogeneic Hematopoietic Cell Transplantation in Elderly Patients.
41. TRANSPLANTATION AND CELLULAR ENGINEERING: Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk
42. Extramedullary Acute Leukemias prior to and after Allogeneic Hematopoietic Stem Cell Transplantation: a Single Center Study.
43. Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT).
44. Lower Relapse Incidence and Relapse Mortality in Patients Transplanted from a Younger Sibling in HLA-Identical Stem Cell Transplantation: Does Microchimerism Matter?
45. Circulating Angiopoietin-2 Predicts Time to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
46. FLAMSA Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in High Risk Myeloid Malignancies Is Also Feasible with Partially Mismatched Donors.
47. Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients - A Single Center Study.
48. Atypical Presentations of EBV Reactivation and EBV-Associated PTLD Post-HSCT: Implication for Routine EBV Surveillance after Allogeneic HSCT?.
49. Donor Lymphocyte Infusions from Unrelated Donors for Treatment of Relapsed Chronic Myelogenous Leukemia: Importance of Initial Cell Dose.
50. Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.